Factors associated with physician perceptions of and willingness to recommend inhaled insulin

References

• Editorial. Patient choice stops at inhaled insulin. Lancet 2006;367:1372
   Web of Science ®Google Scholar
• Del Prato S, Blonde L, Martinez L, et al.; on behalf of the EXPERIENCE Trial Team. The effect of the availability of inhaled insulin on glycaemic control in patients with type 2 diabetes failing on oral therapy: the evaluation of Exubera® as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. Diab Med 2008;25:662-70
   PubMed Web of Science ®Google Scholar
• Quattrin TA, Belanger A, Bohannon JHV, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004;27:2622-7
   PubMed Web of Science ®Google Scholar
• Skyler JS, Weinstock RS, Raskin P, et al.; Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:163-5
   Google Scholar
• Skyler JS, Jovanovic L, Klioze S, et al.; Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-85
   PubMed Web of Science ®Google Scholar
• Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-62
   PubMed Web of Science ®Google Scholar
• Barnett AH, Dreyer M, Lange P, et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282-7
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143:549-58
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cappelleri JC, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23
   PubMed Web of Science ®Google Scholar
• Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care 2008;31:430-2
   PubMed Web of Science ®Google Scholar
• Heinemann L. The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol 2008;3:518-29
   Google Scholar
• Rosenstock J, Bergenstal R, DeFronzo RA, et al.; for the 0008 Study Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008;31:2177-82
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther 2010;12:49-55
   PubMed Web of Science ®Google Scholar
• Segal R, Helper CD. Drug choice as a problem-solving process. Med Care 1985;23:967-76
   PubMed Web of Science ®Google Scholar
• Schumock GT, Walton SM, Paark HY, et al. Factors that influence prescribing decisions. Ann Pharmacother 2004;38:557-62
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Physician perception, recommendation and use of insulin pens for patients with type 2 diabetes. Curr Med Res Opin 2008;24:2413-22
   PubMed Web of Science ®Google Scholar
• Grant RW, Wexlr DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care 2007;30:1448-53
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al.; on behalf of the International DAWN Advisory Board. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study (DAWN). Diabetes Care 2005;28:2673-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Lorber DL, Gnuidi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomized trial. Lancet 2010;375:2244-53
   PubMed Web of Science ®Google Scholar
• Amin V, Boss AH, Petrucci RE, et al. Pulmonary functions (over 2 years) in diabetic subjects treated with AfresaTM or usual antidiabetic treatment. Diabetes 2009;58(Suppl 1):A153 (Abstract # 570)
   Google Scholar
• Peyrot M, Rubin RR. How does treatment satisfaction work? Modeling determinants of treatment satisfaction and preference. Diabetes Care 2009;32:1411-17
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients’ cognitive framework. Diabetes 2010;59 (sup 1)
   Google Scholar